KalVista Pharmaceuticals Files 8-K with Board and Compensation Updates
Ticker: KALV · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1348911
| Field | Detail |
|---|---|
| Company | Kalvista Pharmaceuticals, Inc. (KALV) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing
Related Tickers: KALV
TL;DR
KalVista Pharma (KALV) filed an 8-K today covering board changes and exec comp. No major financial news yet.
AI Summary
On December 16, 2024, KalVista Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes information regarding Regulation FD disclosures and financial statements, though specific financial figures or new appointments are not detailed in the provided text.
Why It Matters
Changes in a company's board of directors and executive compensation can signal shifts in strategy, governance, or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — The filing indicates changes in corporate governance and executive compensation, which can introduce uncertainty or signal strategic shifts.
Key Players & Entities
- KalVista Pharmaceuticals, Inc. (company) — Registrant
- December 16, 2024 (date) — Date of Report
- 001-36830 (other) — SEC File Number
- 20-0915291 (other) — IRS Number
FAQ
What specific changes were made to the board of directors?
The provided text indicates that the 8-K filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but does not specify the names of individuals or the nature of the changes.
What are the details of the compensatory arrangements mentioned?
The filing notes 'Compensatory Arrangements of Certain Officers' as an item of information, but the specific details of these arrangements are not included in the provided excerpt.
Are there any new financial statements or exhibits included with this filing?
Yes, the filing lists 'Financial Statements and Exhibits' as an item of information, suggesting that such documents are part of the report.
What is the significance of the 'Regulation FD Disclosure' item?
This indicates that the company is making disclosures that are intended to be available to all investors, preventing selective disclosure of material non-public information.
What was KalVista Pharmaceuticals' former company name?
KalVista Pharmaceuticals, Inc. was formerly known as Carbylan Therapeutics, Inc. (name change on 20140916) and Carbylan Biosurgery, Inc. (name change on 20130102 and 20060105).
Filing Stats: 1,105 words · 4 min read · ~4 pages · Grade level 11.5 · Accepted 2024-12-16 07:07:31
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 Par Value Per Share KALV The Nasdaq
- $500,000 — that provides for (i) a base salary of $500,000 per year, (ii) an annual bonus target e
Filing Documents
- d866245d8k.htm (8-K) — 31KB
- d866245dex991.htm (EX-99.1) — 9KB
- 0001193125-24-279016.txt ( ) — 165KB
- kalv-20241216.xsd (EX-101.SCH) — 3KB
- kalv-20241216_lab.xml (EX-101.LAB) — 18KB
- kalv-20241216_pre.xml (EX-101.PRE) — 11KB
- d866245d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description of Exhibit 99.1 Press Release issued December 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALVISTA PHARMACEUTICALS, INC. Date: December 16, 2024 By: /s/ Brian Piekos Brian Piekos Chief Financial Officer